Antimicrobial Resistance - Novel coalition sets out to tackle the next global health crisis

A diverse range of sectors and industries come together in partnership to address infection management, advocating a whole system approach
After the uncomfortably close encounter with COVID-19, concerns are rising that antibiotic resistant infections are already presenting the next global health crisis.
In a bid to tackle this 'hidden pandemic', the Infection Management Coalition (IMC) has launched their whitepaper outlining a call for transformational change in the way infection is detected, monitored, prevented, and managed across the NHS, healthcare systems and broader society, by adopting a whole system approach.
The coalition, which comprises partners spanning pharmaceuticals, MedTech and diagnostics, originally came together in January last year to to drive change in support of holistic management and pandemic preparedness in response to the impact the COVID-19 pandemic has had on societies and economies globally.
“Antimicrobial resistance is a growing challenge and an existential threat that we must overcome,” commented Dr David Jenkins, President of the British Society for Antimicrobial Chemotherapy.
The whitepaper, which offers a blueprint for further collaboration, calls for the creation of a "resilient" and "mature" healthcare system with a focus on outbreak and pandemic preparedness, infection prevention, rapid treatment of time-critical viral and bacterial infection, enabling it to ultimately deliver effective antimicrobial stewardship.
Specifically, it includes "tangible recommendations" which break down the siloes within the sector, and identifies owners, timelines, and required actions.
As a next step, the IMC is calling for the development of a cohesive policy to support action, warning that a lack of measures now could result in a pandemic that will have a far greater impact than that seen with COVID-19.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance